The Endocrine Society’s annual conference, ENDO, is set for July 12 through July 15, 2025, in San Francisco, California. The annual event features thousands of abstracts, more than 75 symposia sessions, and dozens of meet-the-professor sessions. 

We’re highlighting some of the neuroendocrinology and pituitary sessions that you may find interesting at ENDO 2025. While this list is accurate as of June 16, 2025, check out the conference’s official website for a complete listing and the most up-to-date information.

July 12

Stalk Lesions of the Pituitary Gland

  • 9:45 AM – 10:30 AM
  • Description: While endocrinologists are more familiar with the evaluation of pituitary incidentaloma, patients with lesions of the pituitary stalk present a different set of differential diagnoses and diagnostic strategies that may be unfamiliar to many endocrinologists. Lesions of the stalk may represent neoplastic, inflammatory, or infiltrative processes. In this session, researchers present causes of pituitary stalk lesions as well as case-based discussion highlighting strategies for imaging and laboratory evaluation.

Amenorrhea Management in Overweight and Underweight Women

  • 9:45 AM – 10:30 AM
  • Description: Amenorrhea due to altered body weight in women is the clinical manifestation of complex endocrine-reproductive interactions that impair hypothalamo-pituitary-ovarian function. Both insufficient and excessive body fat can profoundly disrupt female reproduction and require careful medical history, physical examination, and laboratory assessment to detect their serious adverse consequences on female fertility if not recognized and treated effectively. This session addresses the diagnostic evaluation and management of amenorrhea accompanying altered body weight in women and provides efficient as well as cost-effective medical strategies to optimize the endocrine-reproductive health of these women and their offspring.

Mapping the Hypothalamus One Cell at a Time: RNA-seq at the Forefront

  • 10:45 AM – 12:15 PM
  • Description: Our understanding of the architecture of the hypothalamus has been forever changed with the advent of single-cell RNAseq. An incredible amount of research is focused on the individual cell populations and their roles in physiology. This session features the latest findings in this area, including one of the most important databases developed in the past decade, the HypoMap.

Adrenal Dysregulation and Aging

  • 4:30 PM – 6:00 PM
  • Description: Dysregulation and aging of the adrenal gland can lead to hypercortisolism, affect androgen production and promote the development of adrenal tumors. This session will first focus on new insights into Cushing's syndrome due to GIP-dependent bilateral macronodular adrenal hyperplasia. Secondly, the role of sex steroid precursors and their changes in Cushing's disease and syndrome will be discussed. Finally, the role of aging on adrenal function and tumorigenesis will be evaluated and possible anti-aging strategies will be reviewed.

July 13

An Innovative Approach to Hypoparathyroidism

  • 9:30 AM – 10:30 AM
  • Description: A patient account of their experience with hypoparathyroidism, an overview of missing PTH being the underlying cause of hypoparathyroidism, as well as a review of an innovative treatment, including its mechanism of action, key efficacy and safety findings from the pivotal trail, as well as select dosing and titration information.

Therapeutic Use Exemption in Elite Sport: The Endocrinologist as the Expert for Hormonal Drugs

  • 3:30 PM – 4:15 PM
  • Description: Elite sport demands a level playing field and doping in sports is one of the main ways that that field is tilted. However, some athletes require banned drugs (or methods) to maintain physiological homeostasis, for example, insulin for an athlete with type 1 diabetes mellitus. The diagnosis and therapy of a number of endocrine disorders falls to the adult or pediatric endocrinologist who is the medical expert for conditions of adrenal insufficiency (hydrocortisone and its derivatives are banned). More common are GH deficiency and disturbances of the hypothalamic-pituitary-gonadal axis where hGH, IGF-1 and testosterone are banned drugs. The speaker will review several athlete/patient vignettes and speak about the endocrinologist’s role in helping the athlete to obtain a therapeutic use exemption that will permit them to receive these banned substances to bring them back to their physiological state.

July 14

Perioperative Management of Pituitary Tumors

  • 9:30 AM – 10:15 AM
  • Description: This session will give the opportunity to attendees to identify the preoperative evaluation that should be performed on all pituitary tumor patients prior to surgery. It will also cover the management of immediate postoperative endocrine disorders and will provide postoperative management recommendations for ongoing care. 

Optimizing the Long-term Care of Patients with Acromegaly

  • 9:30 AM – 10:30 AM
  • Description: This session will focus on best practices for achieving comprehensive disease control by addressing both biochemical targets and the ongoing burden of symptoms. Through expert presentation and moderated discussion, we will highlight the importance of integrating consistent IGF-1 monitoring with ongoing symptom assessment to guide effective, long-term management strategies.

Navigating the Complexities & Challenges of Acromegaly Management

  • 12:30 PM – 1:30 PM
  • Description: This session will be a discussion on the complexities and challenges of acromegaly management, focusing on key barriers to optimal patient outcomes. The talk will explore the impact of delayed diagnosis, highlighting how the slow progression of symptoms and overlap with common conditions contribute to a diagnostic delay that may lead to increased morbidity and complications. The session will also cover IGF-1 testing, including its importance, frequency, and assay variability. Challenges in achieving biochemical and symptom control will be addressed, emphasizing treatment goals, adherence issues such as injection fatigue, and the unmet needs, including limitations of current therapies.

Understanding Acquired Hypothalamic Obesity, a Rare Neuroendocrine Disease

  • 12:30 PM – 1:30 PM
  • Description: Experts will discuss strategies to identify, diagnose, and manage acquired hypothalamic obesity early in the incident population as well as in prevalent populations that have had hypothalamic injury as part of their medical history.

Management of Pituitary Tumors During Pregnancy

  • 3:30 PM – 4:15 PM
  • Description: This session will cover the management of micro/macroprolactinomas in pregnancy, the diagnosis and management of Cushing’s disease (challenges with test interpretation, timing/risks of transsphenoidal surgery in gestation; medical therapy with metyrapone; management peri-delivery), and management of acromegaly pre-conception and during gestation. This topic was previously done as a MTP by Mark Molitch in 2018.

July 15

The Neurobiology of GLP1R-Based Anti-Obesity Medications

  • 8:00 AM – 8:45 AM
  • Description: This presentation will cover the neurobiology of GLP-1 receptor (GLP-1R)-based therapies for obesity. It will examine current GLP-1-based therapies, the emergence of GLP-1-based multi-agonists that combine GLP-1 with other hormones, and the potential of GLP-1 peptide-drug conjugates for treating obesity and other disease indications. A key focus will be the central mechanisms of action, including neuroplasticity, which plays a role in appetite regulation, weight loss, and the maintenance of weight loss. The presentation will also explore the potential of GLP-1-based therapies for treating neurodegenerative diseases. Overall, this presentation will provide an overview of the latest advances in GLP-1-based treatments and their broader therapeutic potential.

Adults Craniopharyngiomas: Modern Management and Changes in the Paradigm

  • 8:00 AM – 8:45 AM
  • Description: Recent advances in molecular biology support a reframing of current treatment strategies for papillary craniopharyngiomas. Recent studies confirm that combined BRAF-MEK inhibition can induce a rapid and sustained objective response in these tumors, with encouraging benefits on the associated clinical syndrome and good overall tolerability. Neoadjuvant medical treatment may represent a safe and efficient option for invasive papillary craniopharyngiomas, to facilitate a safer definitive treatment on smaller target volumes, thus improving treatment-related morbidity.

The Functional Impact of Hypothalamic Adult Neurogenesis

  • 9:00 AM – 10:30 AM
  • Description: This session will delve into the emerging role of the hypothalamus as a neurogenic region in the adult brain. Neurogenesis in the adult brain is well-documented in the hippocampus and cortex, and the hypothalamus is emerging as a non-canonical adult neurogenic region. The hypothalamus is especially intriguing as a neurogenic center given its need for plasticity to regulate homeostatic processes such as energy balance, stress, and reproductive functions. However, the level of integration of newly born neurons and their actual influence on hypothalamic physiology remains debated. This session will discuss evidence that adult hypothalamic neurogenesis has a functional impact on physiology.

Unraveling the Complex Central Regulation of Food Intake

  • 10:45 AM – 12:15 PM
  • Description: With the increasing incidence of obesity, there is a need to understand food intake and satiety. The hypothalamus controls energy homeostasis by changing the function of individual neuronal subtypes that either increase or decrease food intake. This symposium will present the latest findings in key neuronal populations and the evidence that these neurons have distinct functions to regulate feeding.

Sign up for alerts and stay informed on upcoming conferences and guideline updates.

Copyright © 2025 Guideline Central, all rights reserved.